WCN24-912 IMAGINATION: A GLOBAL PHASE 3 TRIAL OF RO7434656, AN ANTISENSE OLIGONUCLEOTIDE INHIBITOR OF COMPLEMENT FACTOR B, IN IGA NEPHROPATHY

Saved in:
Bibliographic Details
Main Authors: Jonathan Barratt, Jürgen Flöge, Vishal Duggal, Nadine Schmit, Ji Cheng, Jeannette Lo, Brad Rovin
Format: Article
Language:English
Published: Elsevier 2024-04-01
Series:Kidney International Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024924003929
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849468420896063488
author Jonathan Barratt
Jürgen Flöge
Vishal Duggal
Nadine Schmit
Ji Cheng
Jeannette Lo
Brad Rovin
author_facet Jonathan Barratt
Jürgen Flöge
Vishal Duggal
Nadine Schmit
Ji Cheng
Jeannette Lo
Brad Rovin
author_sort Jonathan Barratt
collection DOAJ
format Article
id doaj-art-30d2eade18b446d4aa355af939dda6f7
institution Kabale University
issn 2468-0249
language English
publishDate 2024-04-01
publisher Elsevier
record_format Article
series Kidney International Reports
spelling doaj-art-30d2eade18b446d4aa355af939dda6f72025-08-20T03:25:52ZengElsevierKidney International Reports2468-02492024-04-0194S14710.1016/j.ekir.2024.02.303WCN24-912 IMAGINATION: A GLOBAL PHASE 3 TRIAL OF RO7434656, AN ANTISENSE OLIGONUCLEOTIDE INHIBITOR OF COMPLEMENT FACTOR B, IN IGA NEPHROPATHYJonathan Barratt0Jürgen Flöge1Vishal Duggal2Nadine Schmit3Ji Cheng4Jeannette Lo5Brad Rovin6Leicester, Department of Cardiovascular Sciences, United KingdomDivision of Nephrology, University Hospital, RheinischWestfälische Technische Hochschule (RWTH) Aachen, AachenClinical Science, Genentech, Inc., South San FranciscoPD Clinical Science, F. Hoffmann-La Roche Ltd, BaselPD Data Sciences, Hoffmann-La Roche Ltd, MississaugaTranslational Medicine, Genentech, Inc., South San FranciscoDepartment of Internal Medicine, The Ohio State University College of Medicine, Columbushttp://www.sciencedirect.com/science/article/pii/S2468024924003929
spellingShingle Jonathan Barratt
Jürgen Flöge
Vishal Duggal
Nadine Schmit
Ji Cheng
Jeannette Lo
Brad Rovin
WCN24-912 IMAGINATION: A GLOBAL PHASE 3 TRIAL OF RO7434656, AN ANTISENSE OLIGONUCLEOTIDE INHIBITOR OF COMPLEMENT FACTOR B, IN IGA NEPHROPATHY
Kidney International Reports
title WCN24-912 IMAGINATION: A GLOBAL PHASE 3 TRIAL OF RO7434656, AN ANTISENSE OLIGONUCLEOTIDE INHIBITOR OF COMPLEMENT FACTOR B, IN IGA NEPHROPATHY
title_full WCN24-912 IMAGINATION: A GLOBAL PHASE 3 TRIAL OF RO7434656, AN ANTISENSE OLIGONUCLEOTIDE INHIBITOR OF COMPLEMENT FACTOR B, IN IGA NEPHROPATHY
title_fullStr WCN24-912 IMAGINATION: A GLOBAL PHASE 3 TRIAL OF RO7434656, AN ANTISENSE OLIGONUCLEOTIDE INHIBITOR OF COMPLEMENT FACTOR B, IN IGA NEPHROPATHY
title_full_unstemmed WCN24-912 IMAGINATION: A GLOBAL PHASE 3 TRIAL OF RO7434656, AN ANTISENSE OLIGONUCLEOTIDE INHIBITOR OF COMPLEMENT FACTOR B, IN IGA NEPHROPATHY
title_short WCN24-912 IMAGINATION: A GLOBAL PHASE 3 TRIAL OF RO7434656, AN ANTISENSE OLIGONUCLEOTIDE INHIBITOR OF COMPLEMENT FACTOR B, IN IGA NEPHROPATHY
title_sort wcn24 912 imagination a global phase 3 trial of ro7434656 an antisense oligonucleotide inhibitor of complement factor b in iga nephropathy
url http://www.sciencedirect.com/science/article/pii/S2468024924003929
work_keys_str_mv AT jonathanbarratt wcn24912imaginationaglobalphase3trialofro7434656anantisenseoligonucleotideinhibitorofcomplementfactorbiniganephropathy
AT jurgenfloge wcn24912imaginationaglobalphase3trialofro7434656anantisenseoligonucleotideinhibitorofcomplementfactorbiniganephropathy
AT vishalduggal wcn24912imaginationaglobalphase3trialofro7434656anantisenseoligonucleotideinhibitorofcomplementfactorbiniganephropathy
AT nadineschmit wcn24912imaginationaglobalphase3trialofro7434656anantisenseoligonucleotideinhibitorofcomplementfactorbiniganephropathy
AT jicheng wcn24912imaginationaglobalphase3trialofro7434656anantisenseoligonucleotideinhibitorofcomplementfactorbiniganephropathy
AT jeannettelo wcn24912imaginationaglobalphase3trialofro7434656anantisenseoligonucleotideinhibitorofcomplementfactorbiniganephropathy
AT bradrovin wcn24912imaginationaglobalphase3trialofro7434656anantisenseoligonucleotideinhibitorofcomplementfactorbiniganephropathy